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Burnet proposed in the 1950’s that the immune system is engaged in identifying and destroying abnormal cancerous cells. This
process, termed immune surveillance, has been at the centre of intense debate for decades. Results using immunodeficient mice lend
support to the immune surveillance hypothesis. We surmised that immune surveillance would be hampered by the inhibitory effect of
naturally occurring FoxP3
þ regulatory T cells, a population of T cells shown to be present at an increased frequency in a variety of
human tumours. The carcinogen, methylcholanthrene was injected subcutaneously into mice and the steady development of
fibrosarcomas was observed over approximately 200 days. These fibrosarcomas were strikingly infiltrated with FoxP3
þ regulatory T
cells implying that these cells impinge upon immune-mediated rejection of the tumour. This was confirmed by partial ablation of
FoxP3
þ regulatory T-cell activity, which resulted in a marked reduction in tumour incidence. The reduction of tumour incidence was
ablated in mice that lacked interferon gamma. These data offer strong support for the concept of immune surveillance and indicate
that this process is limited by the inhibitory effect of FoxP3
þ regulatory T cells.
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Burnet hypothesised in the 1950’s that the adaptive immune
system could control and eliminate developing tumours, a process
later termed tumour immune surveillance (Burnet, 1957).
Although this theory subsequently fell from popularity, a large
body of recent work from different groups has demonstrated an
increase in both spontaneous and carcinogen-induced tumours in
immunocompromised mice including those lacking T cells, natural
killer cells (NK) and natural killer T cells (NKT), type 1 and type 2
interferons, perforin and the IFNg receptor (IFNgR); (reviewed by
Smyth et al, 2006). These experiments have largely been
interpreted as evidence to support the tumour immune surveil-
lance concept and demonstrate the many arms of the immune
system involved in tumour destruction.
CD4
þ FOXP3
þCD25
þ regulatory T cells (Tregs) comprise
approximately 10% of the CD4
þ T-cell population in mice. In
humans, the regulatory CD4
þ T-cell pool is restricted to 1–2% of
the CD4
þ population that are described as CD25
hi (Baecher-Allan
et al, 2001). These cells are thought to be essential for maintaining
tolerance to self-antigens recognised by autoreactive T cells that
escape deletion in the thymus (Sakaguchi, 2005). An absence of
functional Tregs has been associated with several autoimmune
diseases in both animal models (Brunkow et al, 2001) and humans
(Bennett et al, 2001). It was hypothesised that the same Tregs
would have a derogatory impact on antitumour immunity by
inhibiting the activity of T cells that recognise tumour antigens
(Shimizu et al, 1999). Indeed, several groups, including our own,
have shown that depletion of Tregs promotes rejection of tumour
cells lines injected into mice (Onizuka et al, 1999; Shimizu et al
1999; Sutmuller et al, 2001; Golgher et al, 2002). In addition,
evidence from a number of laboratories indicates that higher
frequencies of Tregs are observed in the blood of patients with
cancer compared to healthy subjects (reviewed in Betts et al, 2006).
Results of a study of patients with ovarian cancer indicated that the
frequency of tumour infiltrating Tregs correlated with the extent of
disease thereby implying that Tregs are involved in the pathogen-
esis of cancer (Curiel et al, 2004; Wolf et al, 2005). Furthermore, we
have also recently found that Tregs appear to control antitumour
immune responses in patients with colorectal cancer (Clarke et al,
2006). Despite these observational studies in humans, it is still
unclear whether the frequency and activity of Tregs increases in
response to the tumour or whether tumours are more likely to
develop in individuals with higher frequencies of Tregs, thereby
raising the question of whether Tregs play a role in tumour
immune surveillance. This question cannot be addressed by
inoculation of tumour cell lines as these cells are already endowed
with the necessary mutational and epigenetic changes required to
rapidly produce palpable tumours. Use of these tumours does not
allow for significant interactions between the immune system and
cells in the process of transformation. Models that use carcinogens
do include these early interactions and therefore may be
considered more relevant for deconstructing the relationship
between the immune system and developing tumours. In addition,
the immune system is thought to not only influence tumour
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soutgrowth at the early stages of tumour development but also,
through a sustained interaction with the growing tumour, to
continuously modify and diminish the immunogenicity of the
tumour (Shankaran et al, 2001). Thus, cell lines subjected to
prolonged periods of in vitro culture are almost certainly more
immunogenic than tumour cells in vivo. With this in mind, it is
reasonable to hypothesise that the impact of Tregs on the immune
response to tumours developing in vivo may differ to their impact
on the immune response to tumour cell lines. Injection of the
carcinogen methylcholanthrene (MCA) is an established tumour
induction model that has been used to examine the role of a series
of cell types and signalling molecules that suppress tumour
development. Thus, using MCA, we have examined how altered
frequencies of Tregs impinge on the development of de novo
tumours. Specifically, we determined whether (1) Tregs are present
in MCA-induced tumours, (2) Tregs influence de novo tumour
development, (3) IFNg is required for control of tumour growth in
Treg depleted mice and (4) depletion of Tregs promotes
autoimmunity in MCA-treated mice. The implications of our
findings are discussed in the context of tumour immune
surveillance.
MATERIALS AND METHODS
Mice
Six- to twelve-week-old female wild-type (WT) and IFNg-deficient
(IFNg
 / ) mice on a C57BL/6 (B6, H-2
b) background were sourced
on site. IFNg
 /  mice were originally purchased from the Jackson
Laboratory (Bar harbour, ME , USA) and kindly donated by
Professor N. Topley. Mice were housed in filter top cages and
supplied with sterile food and bedding. Experiments were
performed in compliance with UK Home Office regulations.
Methylcholanthrene injections
A total of 400mg MCA (Sigma-Aldrich, Gillingham, Dorset, UK)
suspended in 100ml olive oil was injected subcutaneously (s.c.)
into the hind leg of the mice. Mice were monitored weekly for
tumour development.
Depletion of CD25
þ cells
Mice were injected intraperitoneally (i.p.) with 0.5mg of the CD25-
specific monoclonal antibody (mAb), PC61 (Lowenthal et al, 1985)
or the isotype control mAb, GL113 at the indicated time points in
100ml PBS before MCA administration.
Flow cytometry
Single-cell suspensions were prepared by filtering mashed tissues
through 70mm nylon strainers (BD falcon, Franklin Lakes, NJ,
USA). Cells were stained with anti-CD4-fluorescein isothiocyanate
(FITC), anti-CD4-PE Alexa 610, anti-CD25-biotin (7D4)/SA-
PerCP-Cy5.5, anti-TCRab Allophycocyanin (APC), anti-FcgIII/II
receptor (BD Franklin Lakes, NJ, USA) and anti-FOXP3-R-
Phycoerythrin (PE) using the ebioscience staining kit (ebioscience,
San Diego, CA, USA, staining kit) mAbs.
Suppression assay
CD4
þ T cells were purified from single-cell suspensions of
splenocytes by magnetic associated cell sorting (MACS) (Miltenyi
Biotec, Auburn, CA, USA). CD4
þCD25
þ cells were separated from
CD4
þCD25
  cells by MACS. CD4
þCD25
  cells (2 10
4) were
stimulated with 1mm anti-CD3 mAb (Leinco, St Louis, MO, USA)
and 1 10
5 mitomycin (Sigma-Aldrich, Gillingham, Dorset, UK)
treated CD4
  splenocytes and incubated with titrated numbers of
CD4
þCD25
þ cells.
Immunohistochemistry
Cryostat-frozen sections (10mm) were dried and fixed with cold
acetone for 15min on ice. Sections were permeabilised with 0.2%
Tween 20, 1% BSA for 30min before a 1-h incubation with rabbit
anti-mouse foxp3 polyclonal antibodies (Ab) (Roncador et al,
2005) and rat anti-mouse mAb (L3T4, BD San Jose, CA, USA) or
rat anti-mouse CD45R/B220 mAb (RA3-6B2, BD Pharmingen San
Jose, CA, USA) or rat anti-mouse CD8 mAb (53-6.7, BD
Pharmingen, San Jose, CA, USA). Sections were subsequently
incubated with biotinylated swine anti-rabbit polyclonal Ab
(DakoCytomation, Carpinteria, CA, USA) followed by Alexa594-
conjugated streptavidin and Alexa488-conjugated goat anti-rat IgG
(Invitrogen, Carlsbad, CA, USA). Sections were mounted (Vecta
Shield, Burlingame, CA, USA) and examined with using a DM LB2
microscope (Leica, Hicksville, NY, USA) and analysed using the
Openlab software package (Improvision, Coventry, Warwickshire,
UK).
Autoantibody detection
Serum was collected from mice and analysed for circulating anti-
double-stranded DNA (dsDNA) IgM autoantibody according to
the manufacturers’ protocol (Alpha Diagnostic, San Antonio, TX,
USA).
Statistical analysis
The extent of Treg infiltration in different organs was compared
using a paired t-test. Comparisons of tumour induction between
experimental groups were made using a log-ranked test.
RESULTS
Treg infiltration of MCA-induced tumours
In preliminary experiments, we found approximately 70–80% of
mice develop fibrosarcomas by day 200 after injection of a high
dose (400mg) of MCA. We first sought to determine whether Treg
infiltrate MCA-induced tumours. Methylcholanthrene-induced
tumours were removed from mice and examined histologically
for Tregs by staining sections with Abs specific for FOXP3 and
CD4. As shown on Figure 1A, tumours were indeed infiltrated with
CD4
þFOXP3
þ Tregs, which were in close proximity to
CD4
þFOXP3
  conventional T cells (Figure 1A) and CD8
þ T cells
(Figure 1B). The majority of infiltrating lymphocytes were
observed at the tumour margin in the interface with healthy leg
muscle (data not shown). These data suggest an ongoing immune
response to the developing tumour, which may be controlled, to
the detriment of the host, by Tregs.
To evaluate further the proportion of Tregs within the tumour
infiltrating lymphocytes (TILs), TILs were stained with CD4-,
CD25- and FOXP3-specific Abs and analysed by flow cytometry.
Supporting the histological observations, approximately half of the
CD4
þ T cells within the TIL expressed FOXP3 (Figure 1C).
Approximately 85% of these cells expressed CD25 (Figure 1D), a
finding that is in agreement with a previous study, which indicated
that, depending on anatomical location, between 20 and 40% of
CD4
þFOXP3
þ cells, do not express CD25 (Fontenot et al, 2005).
Comparisons were made of the Treg frequencies in spleen, blood,
pooled tumour-draining lymph nodes (TDLN) and non-TDLNs
(NTDLN). These data established that Tregs were markedly
enriched in TIL compared to the lymphoid tissues, suggesting
that they are exerting local control of antitumour immune
responses (Figure 1E). A significantly larger proportion of Tregs
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swas also found within the CD4
þ T cells from pooled TDLN mice
compared to pooled NTDLN (Figure 1E). Collectively, these data
clearly indicate that Tregs expand in response to the developing
tumour and are, as described previously in studies using tumour
cell lines (Ghiringhelli et al, 2005), enriched in areas of tumour-
specific immune activity.
Influence of Tregs on development of MCA-induced
tumours
The markedly high infiltrate of Tregs within the fibrosarcomas led
us to explore whether depletion of the Tregs would protect against
the development of MCA-induced tumours.
Depletion of Tregs using the mAb PC61 Depletion of Tregs was
carried out using the CD25-specific, depleting mAb, PC61.
Phenotypic analyses of PC61-treated mice revealed that adminis-
tration of PC61 significantly reduced the number and percentage
of CD4
þFOXP3
þ Tregs in spleens of treated mice (Figure 2A, B).
Thus, treatment with PC61 does not completely remove Tregs for,
as we outlined above, a proportion of CD4
þFOXP3
þ cells express
low or no cell surface CD25 (Fontenot et al, 2005). CD4
þCD25
þ T
cells purified from spleens 3 and 6 weeks following administration
of PC61 were purified and found to exhibit, on a per cell basis,
suppressive capacity comparable to that observed in mice
receiving the control mAb, GL113 (Figure 2C).
Tumour incidence in PC61-treated mice Mice treated as de-
scribed above with either PC61 or control mAbs, were injected 1
day later with MCA mixed in olive oil. Tumour growth was
monitored over 200 days. Figure 2D shows pooled data collected
from three separate experiments with similar results, including one
experiment performed in an animal house at a separate institution.
Twice as many mice in the PC61-treated group remained tumour
free (18/30) compared to the group treated with control Abs (9/30).
These data indicate that even a partial reduction in Treg numbers
results in a highly significant reduction in overall tumour
incidence and delayed tumour development compared to mice
receiving the control mAb, GL113 (P¼0.001) (Figure 2D). Next,
we determined whether additional injections of PC61 would
further reduce MCA-induced tumour incidence. Mice were
injected with PC61 before MCA administration as described
above. Some mice subsequently received further doses of PC61
or isotype control mAb on days 22/24 and 41/43 post-MCA
administration. No difference in tumour incidence was observed
between the two groups (data not shown) indicating that further
injections did not increase the incidence of tumour-free mice. The
effect was not due to neutralisation of the rat mAb in vivo,a sw e
observed that whereas mouse-anti-rat Abs are induced following
administration of PC61, these Abs do not neutralise circulating
PC61 or block the PC61 binding site (data not shown). This failure
to enhance tumour rejection may however be attributable to
codepletion of activated nonregulatory T cells.
Tumour incidence in IFNg
 / , PC61-treated mice IFNg plays an
important role in controlling development of MCA-induced
tumours (Kaplan et al, 1998; Shankaran et al, 2001). In agreement
with these previous studies, we found that whereas only 70% of
WT mice had developed tumours by day 200 after injection with
400mg of MCA, a similar dose induced tumours in all IFNg
 / 
mice by day 160 (compare Figure 2D to Figure 3A). To gain an
insight into the mechanism of tumour rejection in Treg-depleted
animals, we determined whether treatment of IFNg
 /  mice with
CD25-specific mAbs offered protection against the development of
MCA-induced tumours. Depletion of Tregs in these mice did not
offer any protection against tumour development. In fact, tumours
appeared significantly earlier in IFNg
 /  mice treated with CD25-
specific mAbs compared to mice receiving the control mAbs
(Figure 3A). Interestingly, a much smaller percentage (approxi-
mately 40% reduction) of Tregs was observed in tumours excised
from IFNg
 /  mice compared to those from WT mice (Figure 3B).
Similarly, no enrichment of Tregs was observed in the TDLN of
IFNg
 /  mice (data not shown). These data imply that expansion
and/or migration of Tregs in response to a developing tumour is
impaired in the absence of IFNg.
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Figure 1 Methylcholanthrene-induced tumours exhibit a significant
enrichment of CD4
þFOXP3
þ Tregs. Sections of MCA-induced tumours
were stained with anti-FOXP3-specific Ab and either anti-CD4 (A)o r–
CD8 (B) specific mAb. Single-cell suspensions of TILs, NTDLN, TDLN,
spleen and blood were stained with anti-CD4-, anti-CD25- and anti-
FOXP3-specific mAbs and analysed by flow cytometry. A representative
FACS plot of TIL staining is shown and CD4
þFOXP3
þ cells were gated
(R2) (C). This gate was used to examine CD25 expression as shown in the
right panel (D). The percentage of CD4
þ cells expressing FOXP3 in each
compartment is presented (E). Data were analysed using a paired student’s
t-test.
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sCirculating dsDNA specific autoantibodies in
Treg-depleted mice
As a reduction in Treg numbers has been associated with the
development of autoimmunity, circulating autoantibodies were
analysed in mice that remained tumour free following Treg
depletion. Mice treated with PC61 had a significantly elevated
concentration of circulating dsDNA-specific IgM autoantibodies
compared to mice that were not injected with PC61; however, there
was no difference in dsDNA-specific autoantibody levels in mice
treated with PC61 and that remained tumour free compared to
tumour-bearing mice that received PC61 (Figure 4).
DISCUSSION
The aim of the work described here was to directly investigate
whether Tregs impinge on immune surveillance of developing
tumours in vivo. In this study, we used MCA, a carcinogen that has
been widely used to identify a role of a series of immune cell types
and signalling molecules that suppress tumour development. The
study revealed several interesting findings. We first found a
significant enrichment of CD4
þFOXP3
þ Tregs in tumours
developing in vivo, where approximately half of total CD4
þ TIL
were FOXP3
þ. Moreover, injection of mice with the CD25-specific
mAb, PC61, resulted in a transient depletion of a proportion of the
Tregs before MCA injection and a significantly reduced tumour
incidence. We believe that interesting parallels can be drawn
between this work and a study performed 20 years previously by
Prehn and Kojima (1986). Working on the premise that ‘the
presence of autoimmunity implies an increased antitumour
immunity’, Prehn and Kojima (1986)found that 3-day thymectomy
inhibited development of tumours using a high dose of MCA.
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Figure 2 Incidence of MCA-induced tumours is significantly reduced in
Treg-depleted mice. The ability of anti-CD25-specific Ab PC61 to deplete
CD4
þFOXP3
þ Tregs was assessed by analysing the Treg infiltration of
spleens following treatment with the mAb PC61 or the isotype control,
GL113. Spleens were harvested at 3 days, 1 week, 3 weeks, 6 weeks and
16 weeks after injection and the percentage of CD4
þ cells that ex-
press FOXP3 (A), and the total number of CD4
þFOXP3
þ splenocytes
(B) were measured. The suppressive capacity of Tregs following PC61
injection was measured in an in vitro suppression assay (C). Data were
analysed using an unpaired student’s t-test. Mice were treated with 1mg of
either PC61 or isotype control GL113 mAb before the injection of MCA.
The rate of tumour induction, representing the cumulative data from three
experiments, is presented (D). Log-rank statistical analysis was used to
determine the difference in tumour induction between experimental
groups.
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Figure 3 IFNg deficiency abrogates the ability of Treg depletion to
reduce tumour development. IFNg
 /  and WT mice were treated with
1mg of either PC61 or isotype control GL113 mAb before the injection of
MCA and tumour development was monitored (A). Log-rank statistical
analysis was used to determine the difference in tumour induction between
experimental groups. Single-cell suspensions were prepared from tumours
excised from WT and IFNg
 /  tumour bearing mice and stained with anti-
CD4 FITC, anti-CD25 PerCP-Cy5.5 and anti-FOXP3 PE-specific mAbs.
The percentage of CD4
þ TIL that expressed FOXP3 in IFNg
 /  and WT
derived tumours was compared and analysed using an unpaired student’s
t-test (B).
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sBased on the observation that thymic production of CD25
þ T
cells, capable of suppressing the activity of autoreactive T cells,
begins only on day 3 after birth in mice (Asano et al, 1996). It
appears that inhibition of tumour development by day-3
thymectomy and by injection of the CD25-specific mAb, PC61,
occurs by ablation of Treg activity. Ambrosino et al (2006) recently
described treatment of Erbb2 transgenic mice with the CD25-
specific mAb, PC61. These animals develop multiple mammary
carcinomas as a result of overexpression of the Erbb2 oncogene.
PC61-treated mice demonstrated reduced carcinoma multiplicity
and a concomitant increase in immune responses to p185, the
protein product of Errb2 (Ambrosino et al, 2006). In our study, we
found that circulating dsDNA-specific IgM Abs were elevated in
Treg-depleted, MCA-injected mice compared to control mice
implying that Treg depletion drives autoreactivity. Collectively,
these studies indicate that Tregs inhibit immune surveillance and
support the premise that the involvement of Tregs in this process
is a consequence of their role in limiting self-reactive immune
responses.
The key question arising from our data relates to the type of
effector cells promoting tumour rejection after depletion of Tregs.
As Tregs have been shown to suppress both innate and adaptive
immune responses to tumours (reviewed by Betts et al, 2006), it is
likely that multiple arms of the immune system including both
antigen-specific T cells and nonspecific inflammatory responses
are more effective following Treg depletion. In the case of MCA-
induced tumours, Nishikawa et al (2005) recently showed that
Tregs, induced by immunisation with a SEREX-defined self-
antigen expressed in tumour cells, inhibited NK and NKT cells
capable of inhibiting the development of MCA-induced tumours,
thus indicating that these cells are targets of Treg activity and
important antitumour effector cells (Nishikawa et al, 2005).
Ongoing studies in our laboratory are seeking to define precisely
the nature of the antitumour responses induced in Treg-depleted,
MCA-injected mice.
Previous studies have highlighted a critical role for IFNg in
controlling the development of MCA-induced tumours (Kaplan
et al, 1998; Shankaran et al, 2001). IFNg can control tumour
growth directly through proapoptotic, antiangiogenic and anti-
proliferative effects and indirectly, by facilitating induction of
antitumour innate and adaptive immune responses (reviewed by
Smyth et al, 2006). Our study shows that the effect of depleting
Tregs is lost in mice lacking IFNg. This may be because immune
responses uncovered by Treg depletion mediate tumour rejection
through production of IFNg and/or that immune responses
uncovered by Treg depletion cannot compensate for the lack of
IFNg, which is critical for tumour control even in the absence of
Tregs. Interestingly and in contrast to our observations in wild-
type mice, tumours appeared slightly yet significantly earlier in
IFNg
 /  mice receiving CD25-specific mAbs compared to those
that received control mAbs. This finding suggests a fundamental
difference in the response of wild-type and IFNg
 /  mice to MCA
injection. It is possible that CD25-specific mAbs deplete important
tumour-induced effector cells in IFNg
 /  mice. Alternatively, the
impact of Treg activity on tumour development may differ between
IFNg
 /  and wild-type mice. Tregs have been shown in some
experimental models to suppress tumour progression by inhibiting
inflammatory responses that would otherwise promote tumour
development (Erdman et al, 2003). Such inflammatory responses
might be induced in response to MCA injection in IFNg
 /  mice,
thus the overall influence of Tregs would be to suppress tumour
progression through limiting these responses. We did however
observe that IFNg
 /  mice, when challenged with MCA, demon-
strate a reduction of the percentage of CD4
þFOXP3
þ Tregs within
tumours and TDLN. As mentioned earlier, this may reflect a role
for IFNg in expansion/migration of Treg cells or an overall increase
in the expansion of effector T cells in the IFNg
 /  animals.
Interestingly, the function of Tregs has previously been shown to
be impaired in these mice (Kelchtermans et al, 2005). Furthermore,
Wang et al (2006) recently showed that IFNg is important for the
conversion of CD4
þCD25
 FOXP3
  cells to CD4
þCD25
þFOXP3
þ
Tregs, thus it is possible that those CD4
þFOXP3
þ Tregs in MCA-
induced tumours are derived from CD4
þCD25
 FOXP3
  cells by a
process, which is IFNg dependent.
An accumulation of data obtained in studies of patients with
cancer does support the concept that Treg depletion will have a
beneficial effect in cancer immunotherapy. Overall, the results of
this study support this premise by revealing a role for Tregs in
suppressing effective immune surveillance of carcinogen-induced
tumours in intact animals. A more cautionary note, implied by the
findings of this study is that the nature of the ongoing immune
response to the tumour may alter the outcome of Treg depletion, in
some cases favouring tumour progression rather than tumour
control. Further studies are clearly required to clarify this issue.
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Serum from naı ¨ve mice and mice injected with MCA after treatment with
PC61 or GL113 was collected and tested for dsDNA-specific IgM
autoantibody and analysed with an unpaired student’s t-test.
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